EU/3/13/1159

About

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in October 2013 on request of the sponsor.

On 17 July 2013, orphan designation (EU/3/13/1159) was granted by the European Commission to Gilead Sciences International Ltd, United Kingdom, for idelalisib for the treatment of follicular lymphoma.

For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.

Key facts

Active substance
Idelalisib
Disease / condition
Treatment of follicular lymphoma
Date of first decision
17/07/2013
Outcome
Withdrawn
EU designation number
EU/3/13/1159

Review of designation

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in October 2013 on request of the sponsor, before a marketing authorisation had been granted.

Sponsor's contact details

Gilead Sciences International Limited
Flowers Building
Granta Park
Abington
Cambridge
CB21 6GT
United Kingdom
Tel. +44 (0)1223 897300
Fax +44 (0)1223 897284
E-mail: regulatory.orphan@gilead.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating